Miyagawa I, et al. - Experts gauged the selection of specific biological DMARDs (bDMARDs) based on characteristic lymphocyte phenotypes for treating psoriatic arthritis (PsA). Significantly higher efficacy was demonstrated by the strategic treatment in which different bDMARDs were selected according to phenotypic differences in helper T cells than standard bDMARD therapy, indicating the value of precision medicine. They noted a significant decrease in simplified disease activity index (SDAI), DAS28 (ESR) and psoriasis area and severity index after 6 months of strategic treatment. About 92.3% patients achieved low disease activity by SDAI.